Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
Daniel J. Tenney(Bristol-Myers Squibb (Germany)), Richard J. Colonno(Assembly Biosciences (United States)), Ronald E. Rose(Bristol-Myers Squibb (United States)), Betsy J. Eggers(Bristol-Myers Squibb (United States)), Joanna Yang(Bristol-Myers Squibb (United States)), Carl J. Baldick(Bristol-Myers Squibb (United States)), Richard B. Wilber(Bristol-Myers Squibb (United States)), Kevin A. Pokornowski(Bristol-Myers Squibb (United States)), Michael Wichroski(Bristol-Myers Squibb (Germany)), Jie Fang(Chinese Academy of Sciences), Dong Xu(Bristol-Myers Squibb (United States))
Cited by 815
Related Papers
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B
|Gastroenterology|2006|414
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
|Hepatology|2006|348
Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present
|Antimicrobial Agents and Chemotherapy|2006|239